Cargando…
Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patie...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/ https://www.ncbi.nlm.nih.gov/pubmed/35883927 http://dx.doi.org/10.3390/children9070943 |
_version_ | 1784755379969720320 |
---|---|
author | Giljević, Jasminka Stepan Rajačić, Nada Mikulić, Danko Batoš, Ana Tripalo |
author_facet | Giljević, Jasminka Stepan Rajačić, Nada Mikulić, Danko Batoš, Ana Tripalo |
author_sort | Giljević, Jasminka Stepan |
collection | PubMed |
description | To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patients with HRNB, 11 received up to five cycles of dinutuximab beta as part of multimodal therapy; 12 patients did not (i.e., no immunotherapy). In the no immunotherapy group, one patient had complete remission (8%), and 11 patients died of tumor progression (92%). In the dinutuximab beta group, eight patients had complete remission (73%; median duration of response 5 years and 2 months), one had stable disease (9%), and two died of disease (18%). Patients who received dinutuximab beta had a higher median event-free survival (40.0 months [range: 12.5–83.0]) and median overall survival (56.0 months [range: 16.2–101.0]) than those who did not (12.9 months [range: 3.3–126.0] and 20.7 months [3.3–126.0], respectively). Dinutuximab beta was generally well tolerated; adverse events were manageable and as reported in clinical studies. These results confirm the benefits and feasibility of maintenance therapy with dinutuximab beta as part of multimodal therapy for patients with HRNB in real-world clinical practice. |
format | Online Article Text |
id | pubmed-9318789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93187892022-07-27 Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia Giljević, Jasminka Stepan Rajačić, Nada Mikulić, Danko Batoš, Ana Tripalo Children (Basel) Article To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patients with HRNB, 11 received up to five cycles of dinutuximab beta as part of multimodal therapy; 12 patients did not (i.e., no immunotherapy). In the no immunotherapy group, one patient had complete remission (8%), and 11 patients died of tumor progression (92%). In the dinutuximab beta group, eight patients had complete remission (73%; median duration of response 5 years and 2 months), one had stable disease (9%), and two died of disease (18%). Patients who received dinutuximab beta had a higher median event-free survival (40.0 months [range: 12.5–83.0]) and median overall survival (56.0 months [range: 16.2–101.0]) than those who did not (12.9 months [range: 3.3–126.0] and 20.7 months [3.3–126.0], respectively). Dinutuximab beta was generally well tolerated; adverse events were manageable and as reported in clinical studies. These results confirm the benefits and feasibility of maintenance therapy with dinutuximab beta as part of multimodal therapy for patients with HRNB in real-world clinical practice. MDPI 2022-06-23 /pmc/articles/PMC9318789/ /pubmed/35883927 http://dx.doi.org/10.3390/children9070943 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Giljević, Jasminka Stepan Rajačić, Nada Mikulić, Danko Batoš, Ana Tripalo Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia |
title | Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia |
title_full | Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia |
title_fullStr | Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia |
title_full_unstemmed | Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia |
title_short | Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia |
title_sort | dinutuximab beta in children with high-risk neuroblastoma: experience from a single center in croatia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/ https://www.ncbi.nlm.nih.gov/pubmed/35883927 http://dx.doi.org/10.3390/children9070943 |
work_keys_str_mv | AT giljevicjasminkastepan dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia AT rajacicnada dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia AT mikulicdanko dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia AT batosanatripalo dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia |